Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1.0%
    Check dated 2025-06-19T20:09:05.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:24:39.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:09:30.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The webpage has updated its date references, adding two new dates in May 2025 while removing two older dates from February 2022.
    Difference
    0.8%
    Check dated 2025-05-22T03:42:59.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T16:46:37.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The page has been updated to include new information about a clinical trial for metastatic renal cell cancer, including the addition of a new principal investigator and collaborators, while significant details about the trial's objectives and treatment methods have been removed.
    Difference
    45%
    Check dated 2025-04-16T12:22:32.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.